We paid special attention to the HIF2α/VEGF signals since these two downstream targets of VHL have been reported to promote cancer progression via promoting angiogenesis [14] and were two of the essential targets for the current therapies for advanced RCC [27]. The gene discussed is EPAS1; the disease is renal cell carcinoma.